In the preclinical model of PD, gene ablation of MLKL or RIPK3 or pharmacological inhibition of RIPK1 reduced the degeneration of dopaminergic neurons, improved motor ability and played a neuroprotective role. Here, MLKL is linked to Parkinson disease.